Thyroid Cancer—Risks and Causes

Oncology & Hematology Review, 2014;10(2):144–51


The incidence of thyroid cancer has almost doubled in recent years and over 60,000 people will be diagnosed in the US in 2015. While the prognosis for most such patients is excellent, a significant proportion die of thyroid cancer from local tumor progression and above all from metastases. Here we review the different types of thyroid cancers and their molecular changes with a special emphasis on the currently known susceptibility and precipitating factors. With the recent clinical introduction of tyrosine kinase inhibitors for the treatment of metastatic thyroid cancer it is clear that a simple cure is not at hand and further understanding of the molecular mechanisms of these tumors is urgently needed.

Keywords: Thyroid, cancer, follicular, papillary, anaplastic, mutations, gene fusions, susceptibility genes, radioiodine, TSH, autoimmunity, nodules, EMT
Disclosure: Simon Bonnefond, MD, and Terry F Davies, MD, FRCP, FACE have no conflicts of interest to declare. No funding was received in the publication of this article.
Received: August 22, 2014 Accepted October 08, 2014 Citation Oncology & Hematology Review, 2014;10(2):144–51
Correspondence: Terry F Davies, Box 1055, Mount Sinai Medical Center, 1 Gustave L Levy Place, New York, NY 10029, US. E:

Thyroid cancer is the most common endocrine cancer, representing about 1 % of all malignancies diagnosed worldwide, with approximately 600,000 men and women alive in the US who have a history of cancer of the thyroid ( cts/html/thyro.html). Despite its prevalence, the mortality from thyroid cancer remains relatively low at ~0.5 per 100,000 population per year as a result of the availability of effective therapies for most types of the disease. The exception to this is the anaplastic subtype, which is ranked among the most deadly of all human cancers.

While the incidence of many cancers has remained stable or even decreased in recent years, thyroid cancer incidence has significantly increased with an annual percentage change of 6.4 % for males and females in the US over the period 1997–2010 ( cts/html/thyro.html) (see Figure 1A). There is variation between countries that could be explained by differences in environmental exposure, genetic factors, or access to healthcare (see Figure 1B). It is estimated that 60,000 men and women (15,000 men and 45,000 women) will be diagnosed with the disease in 2014 and almost 2,000 will die. The reasons for this increased incidence are controversial and most likely multifactorial. Increased detection of preclinical stage tumors of small size would appear to be an obvious cause with the introduction and widespread use of thyroid sonography and increased use of aspiration biopsies of small tumor as suggested by Davies and Welch.1,2This explanation for earlier diagnosis and identification of small tumors is supported by the lack of increase in thyroid cancer mortality. But many experts claim that the rising incidence of thyroid cancer cannot be explained by improvements in screening and detection,3–5 as an increase has occurred in large tumors especially papillary thyroid cancer but no significant change for the follicular, medullary, or anaplastic histotypes.1,5 A true increase could be the result of a change in exposure to an unidentified risk factor in the environment or in our lifestyle. To date, ionizing radiation is the best-established risk factor for thyroid cancer, as a result of data obtained from nuclear incidents such as the Chernobyl radioiodine releases and from Hiroshima and Nagasaki. Many studies have focused on other possible risk factors, which we will review.

Patients die of thyroid cancer from local tumor progression and above all from metastases. Epithelial to mesenchymal transition (EMT) is thought to play a major role in tumor genesis/invasion and spread of metastases in many cancers including thyroid cancer. The relationship between cancer cells, EMT, and cancer stem cells (CSCs) is poorly understood although it has been shown that certain epithelial cancer cells that pass through EMT acquire CSC properties including thyroid cancer cells.6,7 Determining the mechanisms by which known risk factors such as EMT initiation could potentially lead to the development of new specific targets for thyroid cancer.

The goal of this review, therefore, is to summarize the risk factors and susceptibilities for thyroid cancer in order to lead to the development of new and more-effective therapeutic targets. Moreover, detailed examination of population-level risk factors can help identify and support prevention efforts to reduce the disease burden.

The Different Types of Thyroid Cancer
Thyroid cancers are still categorized by their histologic appearance and their natural history (see Table 1). The two most common forms of differentiated thyroid cancer are the papillary and follicular types. The papillary form tends not to metastasize outside the neck compared with follicular thyroid cancers, which have a propensity to spread further. This histologic differentiation is now supported by molecular studies (see below). The vast majority of thyroid tumors arise from thyroid follicular epithelial cells but the 3–5 % of medullary cancers originate from the C cells, which secrete calcitonin and are outside the purview of this review.

The well-differentiated thyroid cancers often have an indolent clinical course with low morbidity and mortality. With some exceptions, these are among the most curable of cancers and, as a consequence, patients are sometimes ill advised that thyroid cancer is not a serious problem. Although anaplastic thyroid cancer (ATC), which is highly aggressive and accounts for ~50 % of all thyroid cancer-related deaths, remains uncommon, more malignant forms of differentiated thyroid cancer exist, such as the tall cell variant of papillary thyroid cancer8 and the Hurtle cell follicular cancers,9,10 which can be difficult to treat.

  1. Davies L, Welch HG, Increasing incidence of thyroid cancer in the United States, 1973–2002, JAMA, 2006;295:2164–7.
  2. Davies L, Welch HG, Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg, 2014;140:317–22.
  3. Aschebrook-Kilfoy B, Grogan RH, Ward MHI, et al., Follicular thyroid cancer incidence patterns in the United States, 1980–2009, Thyroid, 2013;23:1015–21.
  4. Enewold L, Zhu K, Ron E, et al., Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005, Cancer Epidemiol Biomarkers Prev, 2009;18:784–91.
  5. Chen AY, Jemal A, Ward EM, Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005, Cancer, 2009;115:3801–7.
  6. Phay JE, Ringel MD, Metastatic mechanisms in follicular cellderived thyroid cancer, Endocr Relat Cancer, 2013;20:R307–19.
  7. Ma R, et al., Stemness is derived from thyroid cancer cells, Front Endocrinol (Lausanne), 2014;5:114.
  8. Hawk WA, Hazard JB, The many appearances of papillary carcinoma of the thyroid, Cleve Clin Q, 1976;43:207–15.
  9. Hundahl SA, Cady B, Cunningham MP et al., Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study, Cancer, 2000;89:202–17.
  10. Dahl LD, Myssiorek D, Heller KS, Hurthle cell neoplasms of the thyroid, Laryngoscope, 2002;112:2178–80.
  11. DeLellis RA, Pathology and genetics of tumours of endocrine organs, World Health Organization Classification of Tumours, 2004, Lyon: IARC Press, 320.
  12. Venkatesh YS, Ordonez NG, Schultz PN, et al., Anaplastic carcinoma of the thyroid, A clinicopathologic study of 121 cases, Cancer, 1990;66:321–30.
  13. Bronner MP, LiVolsi VA, Spindle cell squamous carcinoma of the thyroid: an unusual anaplastic tumor associated with tall cell papillary cancer, Mod Pathol, 1991;4:637–43.
  14. Yoshida A, Nakamura Y, Imada T, et al., Apoptosis and proliferative activity in thyroid tumors, Surg Today, 1999;29:204–8.
  15. Ryder M, Ghossein RA, Ricarte-Filho JC, et al., Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer, Endocr Relat Cancer, 2008;15:1069–74.
  16. Aldinger KA, Samaan NA, Ibanez M, Hill CS, Jr., et al., Anaplastic carcinoma of the thyroid: a review of 84 cases of spindle and giant cell carcinoma of the thyroid, Cancer, 1978;41:2267–75.
  17. Lam KY, Lo CY, Chan KW, Wan KY, Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21, Ann Surg, 2000;23:329–38.
  18. Stratton MR, Exploring the genomes of cancer cells: progress and promise, Science, 2011;331:1553–8.
  19. Cheng G, Lewis AE, Meinkoth JL, Ras stimulates aberrant cell cycle progression and apoptosis in rat thyroid cells, Mol Endocrinol, 2003;17:450–9.
  20. Liu X, Bishop J, Shan Y, et al., Highly prevalent TERT promoter mutations in aggressive thyroid cancers, Endocr Relat Cancer, 2013;20:603–10.
  21. Hodak SP, Rosenthal DS, Information for clinicians: commercially available molecular diagnosis testing in the evaluation of thyroid nodule fine-needle aspiration specimens, Thyroid, 2013;23:131–4.
  22. Khan A, Smellie J, Nutting C, et al., Familial nonmedullary thyroid cancer: a review of the genetics, Thyroid, 2010;20:795–801.
  23. Kohler A, Chen B, Gemignani F, et al., Genome-wide association study on differentiated thyroid cancer, J Clin Endocrinol Metab, 2013;98:E1674–81.
  24. Jendrzejewski J, He H, Radomska HS, et al., The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type, Proc Natl Acad Sci U S A, 2012;109:8646–51.
  25. Bastos HN, Antao MR, Silva SN, et al., Association of polymorphisms in genes of the homologous recombination DNA repair pathway and thyroid cancer risk, Thyroid, 2009;19:1067–75.
  26. Fallah M, Pukkala E, Tryggvadottir L, et al., Risk of thyroid cancer in first-degree relatives of patients with non-medullary thyroid cancer by histology type and age at diagnosis: a joint study from five Nordic countries, J Med Genet, 2013;50:373–82.
  27. McDonald TJ, Driedger AA, Garcia BM, et al., Familial papillary thyroid carcinoma: a retrospective analysis, J Oncol, 2011;2011:948786.
  28. Socolow, EL, Hashizume A, Neriishi S, Niitani R, Thyroid carcinoma in man after exposure to ionizing radiation. A summary of the findings in Hiroshima and Nagasaki, N Engl J Med, 1963;268:406–10.
  29. Fushiki S, Radiation hazards in children – Lessons from Chernobyl, Three Mile Island and Fukushima, Brain and Development, 2013;35:220–7
  30. Williams D, Radiation carcinogenesis: lessons from Chernobyl, Oncogene, 2008;27 Suppl. 2:S9–18.
  31. Ron E, Lubin JH, Shore RE, et al., Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies, Radiat Res, 1995;141:259–77.
  32. Mettler FA, Jr., Thomadsen BR, Bhargavan M, et al., Medical radiation exposure in the U.S. in 2006: preliminary results, Health Phys, 2008;95:502–7.
  33. Berrington de Gonzalez A, Mahesh M, Kim KP, et al., Projected cancer risks from computed tomographic scans performed in the United States in 2007, Arch Intern Med, 2009;169:2071–7.
  34. Caudill CM, Zhu Z, Ciampi R, et al., Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to gamma-radiation: a model of carcinogenic chromosomal rearrangement induced by ionizing radiation. J Clin Endocrinol Metab, 2005;90:2364–9.
  35. Hamatani K, Eguchi H, Ito R, et al., RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose, Cancer Res, 2008;68:7176–82.
  36. Richardson DB, Exposure to ionizing radiation in adulthood and thyroid cancer incidence, Epidemiology, 2009;20:181–7.
  37. Chuang SC, Hashibe M, Yu GP, et al., Radiotherapy for primary thyroid cancer as a risk factor for second primary cancers, Cancer Lett, 2006;238:42–52.
  38. Bhatti P, Veiga LH, Ronckers CM, et al., Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor study, Radiat Res, 2010;174:741–52.
  39. Franklyn JA, Maisonneuve P, Sheppard M, et al., Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study, Lancet, 1999;353:2111–5.
  40. Fang WT, Qao BS, Wang JB, [Iodine deficiency induces thyroid cancer in rats and mice], Zhonghua Zhong Liu Za Zhi, 1994;16:341–4.
  41. Cardis E, Kesminiene A, Ivanov V, et al., Risk of thyroid cancer after exposure to 131I in childhood. J Natl Cancer Inst, 2005;97:724–32.
  42. Guan H, Ji M, Bao R, et al., Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer, J Clin Endocrinol Metab, 2009;94:1612–7.
  43. Mathur A, Moses W, Rahbari R, et al., Higher rate of BRAF mutation in papillary thyroid cancer over time: a singleinstitution study, Cancer, 2011;117:4390–5.
  44. Shakhtarin VV, Tsyb AF, Stepanenko VF, et al., Iodine deficiency, radiation dose, and the risk of thyroid cancer among children and adolescents in the Bryansk region of Russia following the Chernobyl power station accident, Int J Epidemiol, 2003;32:584–91.
  45. Carstensen JM, Wingren G, Hatschek T, et al., Occupational risks of thyroid cancer: data from the Swedish Cancer-Environment Register, 1961–1979, Am J Ind Med, 1990;18:535–40.
  46. Lope V, Perez-Gomez B, Aragones N, et al., Occupational exposure to chemicals and risk of thyroid cancer in Sweden, Int Arch Occup Environ Health, 2009;82:267–74.
  47. Pellegriti G, De Vathaire F, Scollo C, et al., Papillary thyroid cancer incidence in the volcanic area of Sicily, J Natl Cancer Inst, 2009;101:1575–83.
  48. Zamora-Ros R, Rinaldi S, Biessy C, et al., Reproductive and menstrual factors and risk of differentiated thyroid carcinoma: The EPIC study, Int J Cancer, 2014 [Epub ahead of print].
  49. Yane K, Kitahori Y, Konishi N, et al., Expression of the estrogen receptor in human thyroid neoplasms, Cancer Lett, 1994;84:59–66.
  50. Takeichi N, Ito H, Haruta R, et al., Relation between estrogen receptor and malignancy of thyroid cancer, Jpn J Cancer Res, 1991;82:19–22.
  51. Messuti I, Corvisieri S, Bardesono F, et al., Impact of pregnancy on prognosis of differentiated thyroid cancer: clinical and molecular features, Eur J Endocrinol, 2014;170:659–66.
  52. Yasmeen S, Cress R, Romano PS, et al., Thyroid cancer in pregnancy, Int J Gynaecol Obstet, 2005;91:15–20.
  53. Renehan AG, Tyson M, Egger M, et al., Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies, Lancet, 2008;371:569–78.
  54. Aschebrook-Kilfoy B, Sabra MM, Brenner A, et al., Diabetes and thyroid cancer risk in the National Institutes of Health-AARP Diet and Health Study. Thyroid, 2011;21:957–63.
  55. Dumont JE, Maenhaut C, Pirson I, et al., Growth factors controlling the thyroid gland, Baillieres Clin Endocrinol Metab, 1991;5:727–54.
  56. Tominaga T, Dela Cruz J, Burrow GN, Meinkoth JL, Divergent patterns of immediate early gene expression in response to thyroid-stimulating hormone and insulin-like growth factor I in Wistar rat thyrocytes, Endocrinology, 1994;135:1212–9.
  57. Rezzonico JN, Rezzonico M, Pusiol E, et al., Increased prevalence of insulin resistance in patients with differentiated thyroid carcinoma, Metab Syndr Relat Disord, 2009;7:375–80.
  58. Cash SW, Ma H, Horn-Ross PL, et al., Recreational physical activity and risk of papillary thyroid cancer among women in the California Teachers Study, Cancer Epidemiol, 2013;37:46–53.
  59. Leitzmann MF, Brenner A, Moore SC, et al., Prospective study of body mass index, physical activity and thyroid cancer, Int J Cancer, 2010;126:2947–56.
  60. Kim HK, Yoon JH, Kim SJ, et al., Higher TSH level is a risk factor for differentiated thyroid cancer, Clin Endocrinol (Oxf), 2013;78:472–7.
  61. Fiore E, Rago T, Provenzale MA, et al., Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role, Endocr Relat Cancer, 2009;16:1251–60.
  62. Haymart MR, Repplinger DJ, Leverson G, et al., Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage, J Clin Endocrinol Metab, 2008;93:809–14.
  63. Boelaert K, Horacek J, Holder RL, et al., Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration, J Clin Endocrinol Metab, 2006;91:4295–301.
  64. Franco AT, Malaguarnera R, Refetoff S, et al., Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice, Proc Natl Acad Sci U S A, 2011;108:1615–20.
  65. Chen YK, Lin CL, Chang YL, et al., Cancer risk in patients with Graves’ disease: a nationwide cohort study, Thyroid, 2013;23:879–84.
  66. Pazaitou-Panayiotou K, Michalakis K, Paschke R, Thyroid cancer in patients with hyperthyroidism, Horm Metab Res, 2012;44:255–62.
  67. Fiore E, Rago T, Latrofa F, et al., Hashimoto’s thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine. Endocr Relat Cancer, 2011;18:429–37.
  68. Anil C, Goksel S, Gursoy A, Hashimoto’s thyroiditis is not associated with increased risk of thyroid cancer in patients with thyroid nodules: a single-center prospective study, Thyroid, 2010;20:601–6.
  69. Holm LE, Blomgren H, Lowhagen T, Cancer risks in patients with chronic lymphocytic thyroiditis, N Engl J Med, 1985;312:601–4.
  70. Carson HJ, Castelli MJ, Gattuso P, Incidence of neoplasia in Hashimoto’s thyroiditis: a fine-needle aspiration study, Diagn Cytopathol, 1996;14:38–42.
  71. Erdogan M, Erdem N, Cetinkalp S, et al., Demographic, clinical, laboratory, ultrasonographic, and cytological features of patients with Hashimoto’s thyroiditis: results of a university hospital of 769 patients in Turkey, Endocrine, 2009;36:486–90.
  72. Azizi G, Malchoff CD, Autoimmune thyroid disease: a risk factor for thyroid cancer, Endocr Pract, 2011;17:201–9.
  73. Larson SD, Jackson LN, Riall TS, et al., Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway, J Am Coll Surg, 2007;204:764–73; discussion 773–5.
  74. Grazia Castagna M, Belardini V, Memmo S, et al., Nodules in autoimmune thyroiditis are associated with increased risk of thyroid cancer in surgical series, but not in cytological series: evidence for selection bias, J Clin Endocrinol Metab, 2014:jc20141302.
  75. Lun Y, Wu X, Xia Q, et al., Hashimoto’s thyroiditis as a risk factor of papillary thyroid cancer may improve cancer prognosis, Otolaryngol Head Neck Surg, 2013;148:396–402.
  76. Coussens, LM, Werb Z, Inflammation and cancer, Nature, 2002;420:860–7.
  77. Imam S, Paparodis R, Sharma D, Carlos Jaume J, et al., Lymphocytic profiling in thyroid cancer provides clues for failure of tumor immunity, Endocr Relat Cancer, 2014;21:505–16.
  78. Zhang Y, Dai J, Wu T, et al., The study of the coexistence of Hashimoto’s thyroiditis with papillary thyroid carcinoma, J Cancer Res Clin Oncol, 2014;140:1021–6.
  79. Teng MW, Smyth MJ, Cancer. Can cancer trigger autoimmunity?, Science, 2014;343:147–8.
  80. Cooper DS, Doherty GM, Haugen BR, et al., Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer, Thyroid, 2009;19:1167–214.
  81. Ma R, Minsky N, Morshed SA, Davies TF, et al., Stemness in human thyroid cancers and derived cell lines: the role of asymmetrically dividing cancer stem cells resistant to chemotherapy, J Clin Endocrinol Metab, 2014;99:E400–9.
  82. Thiery JP, Sleeman JP, Complex networks orchestrate epithelial-mesenchymal transitions, Nat Rev Mol Cell Biol, 2006;7:131–42.
  83. Polyak K, Weinberg RA, Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits, Nat Rev Cancer, 2009;9:265–73.
  84. Cano A, Perez-Moreno MA, Rodrigo I, et al., The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression, Nat Cell Biol, 2000;2:76–83.
  85. Hardy RG, Vicente-Duenas C, Gonzalez-Herrero I, et al., Snail family transcription factors are implicated in thyroid carcinogenesis, Am J Pathol, 2007;171:1037–46.
  86. Davies TF, Latif R, Minsky NC, and Ma R, et al., Clinical review: The emerging cell biology of thyroid stem cells, J Clin Endocrinol Metab, 2011;96:2692–702.
  87. Gandhi M, Evdokimova V, Nikiforov YE, Mechanisms of chromosomal rearrangements in solid tumors: the model of papillary thyroid carcinoma, Mol Cell Endocrinol, 2010;321:36–43.
  88. Nikiforov YE, Nikiforova MN, Molecular genetics and diagnosis of thyroid cancer, Nat Rev Endocrinol, 2011;7:569–80.
  89. Ma R, Latif R, Davies TF, Thyroid follicle formation and thyroglobulin expression in multipotent endodermal stem cells, Thyroid, 2013;23:385–91.
Keywords: Thyroid, cancer, follicular, papillary, anaplastic, mutations, gene fusions, susceptibility genes, radioiodine, TSH, autoimmunity, nodules, EMT